Phase I/II Study of Curdlan Sulfate
To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.
|Study Design:||Endpoint Classification: Safety Study
Primary Purpose: Treatment
|Official Title:||Phase I/II Study of Curdlan Sulfate|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002100
|United States, California|
|San Francisco, California, United States, 94109|